Foundation-directed therapeutic development in Huntington's disease

Journal of Medicinal Chemistry

Volumn 57, Issue 13, 2014, Pages 5479-5488

  Dominguez, Celia ^a   Munoz Sanjuan, Ignacio ^a  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYKYNURENINE; BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE INHIBITOR; MICRORNA; OXYGENASE INHIBITOR; POLYGLUTAMINE; QUINOLINIC ACID; RACLOPRIDE; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; BLOOD BRAIN BARRIER; CAG REPEAT; CLINICAL RESEARCH; DEGENERATIVE DISEASE; GENE EXPRESSION; GENE MUTATION; HEALTH PROGRAM; HUMAN; HUNTINGTON CHOREA; IC 50; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; NON PROFIT ORGANIZATION; NONHUMAN; PALMITOYLATION; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SUMOYLATION; TRANSLATIONAL RESEARCH; UBIQUITINATION;

ANIMALS; BRAIN; FOUNDATIONS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HUNTINGTON DISEASE; KYNURENINE 3-MONOOXYGENASE; NERVE TISSUE PROTEINS; NEURONS; RESEARCH SUPPORT AS TOPIC;

EID: 84904341682     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4009295     Document Type: Review

References (74)

1. Zuccato, C.; Valenza, M.; Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington's disease Physiol. Rev. 2010, 90, 905-981
2. Huntington, G. On chorea Med. Surg. Rep.: Wkly. J. 1872, 26, 317-321
3. Huntington, G. On chorea. George Huntington, M.D J. Neuropsychiatry Clin. Neurosci. 2003, 15, 109-112
4. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72, 971-983.
5. Gusella, J. F.; MacDonald, M. E. Huntington's disease: the case for genetic modifiers Genome Med. 2009, 1, 80
6. Vonsattel, J. P.; DiFiglia, M. Huntington disease J. Neuropathol. Exp. Neurol. 1998, 57, 369-384 (Pubitemid 28237321)
7. Sanberg, P. R.; Fibiger, H. C.; Mark, R. F. Body weight and dietary factors in Huntington's disease patients compared with matched controls Med. J. Aust. 1981, 1, 407-409 (Pubitemid 11041471)
8. Biglan, K. M.; Ross, C. A.; Langbehn, D. R.; Aylward, E. H.; Stout, J. C.; Queller, S.; Carlozzi, N. E.; Duff, K.; Beglinger, L. J.; Paulsen, J. S. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study Mov. Disord. 2009, 24, 1763-1772
9. Duff, K.; Paulsen, J. S.; Beglinger, L. J.; Langbehn, D. R.; Stout, J. C. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study Biol. Psychiatry 2007, 62, 1341-1346 (Pubitemid 350180721)
10. Duff, K.; Paulsen, J. S.; Beglinger, L. J.; Langbehn, D. R.; Wang, C.; Stout, J. C.; Ross, C. A.; Aylward, E.; Carlozzi, N. E.; Queller, S. "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness J. Neuropsychiatry Clin. Neurosci. 2010, 22, 196-207
11. Fischbeck, K. H. Polyglutamine expansion neurodegenerative disease Brain Res. Bull. 2001, 56, 161-163 (Pubitemid 33062337)
12. Margolis, R. L.; Ross, C. A. Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases Trends Mol. Med. 2001, 7, 479-482 (Pubitemid 33021670)
13. Hayden, M. R.; MacGregor, J. M.; Beighton, P. H. The prevalence of Huntington's chorea in South Africa S. Afr. Med. J. 1980, 58, 193-196 (Pubitemid 10036596)
14. Wright, H. H.; Still, C. N.; Abramson, R. K. Huntington's disease in black kindreds in South Carolina Arch. Neurol. 1981, 38, 412-414 (Pubitemid 11086892)
15. Folstein, S. E.; Chase, G. A.; Wahl, W. E.; McDonnell, A. M.; Folstein, M. F. Huntington disease in Maryland: clinical aspects of racial variation Am. J. Hum. Genet. 1987, 41, 168-179 (Pubitemid 17145616)
16. Hilditch-Maguire, P.; Trettel, F.; Passani, L. A.; Auerbach, A.; Persichetti, F.; MacDonald, M. E. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles Hum. Mol. Genet. 2000, 9, 2789-2797
17. Crook, Z. R.; Housman, D. Huntington's disease: Can mice lead the way to treatment? Neuron 2011, 69, 423-435
18. Hult, S.; Schultz, K.; Soylu, R.; Petersen, A. Hypothalamic and neuroendocrine changes in Huntington's disease Curr. Drug Targets 2010, 11, 1237-1249
19. Cattaneo, E.; Zuccato, C.; Tartari, M. Normal huntingtin function: an alternative approach to Huntington's disease Nat. Rev. Neurosci. 2005, 6, 919-930 (Pubitemid 41753086)
20. Munoz-Sanjuan, I.; Bates, G. P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease J. Clin. Invest. 2011, 121, 476-483
21. Reiner, A.; Dragatsis, I.; Zeitlin, S.; Goldowitz, D. Wild-type huntingtin plays a role in brain development and neuronal survival Mol. Neurobiol. 2003, 28, 259-276
22. Woda, J. M.; Calzonetti, T.; Hilditch-Maguire, P.; Duyao, M. P.; Conlon, R. A.; MacDonald, M. E. Inactivation of the Huntington's disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo BMC Dev. Biol. 2005, 5, 17
23. Andrade, M. A.; Bork, P. HEAT repeats in the Huntington's disease protein Nat. Genet. 1995, 11, 115-116
24. Becher, M. W.; Kotzuk, J. A.; Sharp, A. H.; Davies, S. W.; Bates, G. P.; Price, D. L.; Ross, C. A. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length Neurobiol. Dis. 1998, 4, 387-397 (Pubitemid 28201657)
25. Wexler, N. S.; Lorimer, J.; Porter, J.; Gomez, F.; Moskowitz, C.; Shackell, E.; Marder, K.; Penchaszadeh, G.; Roberts, S. A.; Gayan, J.; Brocklebank, D.; Cherny, S. S.; Cardon, L. R.; Gray, J.; Dlouhy, S. R.; Wiktorski, S.; Hodes, M. E.; Conneally, P. M.; Penney, J. B.; Gusella, J.; Cha, J. H.; Irizarry, M.; Rosas, D.; Hersch, S.; Hollingsworth, Z.; MacDonald, M.; Young, A. B.; Andresen, J. M.; Housman, D. E.; De Young, M. M.; Bonilla, E.; Stillings, T.; Negrette, A.; Snodgrass, S. R.; Martinez-Jaurrieta, M. D.; Ramos-Arroyo, M. A.; Bickham, J.; Ramos, J. S.; Marshall, F.; Shoulson, I.; Rey, G. J.; Feigin, A.; Arnheim, N.; Acevedo-Cruz, A.; Acosta, L.; Alvir, J.; Fischbeck, K.; Thompson, L. M.; Young, A.; Dure, L.; O'Brien, C. J.; Paulsen, J.; Brickman, A.; Krch, D.; Peery, S.; Hogarth, P.; Higgins, D. S., Jr.; Landwehrmeyer, B. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 3498-3503 (Pubitemid 38338224)
26. Figiel, M.; Szlachcic, W. J.; Switonski, P. M.; Gabka, A.; Krzyzosiak, W. J. Mouse models of polyglutamine diseases: review and data table. Part I Mol. Neurobiol. 2012, 46, 393-429
27. Heikkinen, T.; Lehtimaki, K.; Vartiainen, N.; Puolivali, J.; Hendricks, S. J.; Glaser, J. R.; Bradaia, A.; Wadel, K.; Touller, C.; Kontkanen, O.; Yrjanheikki, J. M.; Buisson, B.; Howland, D.; Beaumont, V.; Munoz-Sanjuan, I.; Park, L. C. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease PLoS One 2012, 7, e50717
28. Switonski, P. M.; Szlachcic, W. J.; Gabka, A.; Krzyzosiak, W. J.; Figiel, M. Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II Mol. Neurobiol. 2012, 46, 430-466
29. Kordasiewicz, H. B.; Stanek, L. M.; Wancewicz, E. V.; Mazur, C.; McAlonis, M. M.; Pytel, K. A.; Artates, J. W.; Weiss, A.; Cheng, S. H.; Shihabuddin, L. S.; Hung, G.; Bennett, C. F.; Cleveland, D. W. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis Neuron 2012, 74, 1031-1044
30. Grondin, R.; Kaytor, M. D.; Ai, Y.; Nelson, P. T.; Thakker, D. R.; Heisel, J.; Weatherspoon, M. R.; Blum, J. L.; Burright, E. N.; Zhang, Z.; Kaemmerer, W. F. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum Brain 2012, 135, 1197-1209
31. McBride, J. L.; Pitzer, M. R.; Boudreau, R. L.; Dufour, B.; Hobbs, T.; Ojeda, S. R.; Davidson, B. L. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease Mol. Ther. 2011, 19, 2152-2162
32. Sah, D. W.; Aronin, N. Oligonucleotide therapeutic approaches for Huntington disease J. Clin. Invest. 2011, 121, 500-507
33. Brandt, J.; Folstein, S. E.; Wong, D. F.; Links, J.; Dannals, R. F.; McDonnell-Sill, A.; Starkstein, S.; Anders, P.; Strauss, M. E.; Tune, L. E.; Wagner, H. N.; Folstein, M. F. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates J. Neuropsychiatry Clin. Neurosci. 1990, 2, 20-27 (Pubitemid 20125840)
34. Andre, V. M.; Cepeda, C.; Levine, M. S. Dopamine and glutamate in Huntington's disease: a balancing act CNS Neurosci. Ther. 2010, 16, 163-178
35. Van Laere, K.; Casteels, C.; Dhollander, I.; Goffin, K.; Grachev, I.; Bormans, G.; Vandenberghe, W. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo J. Nucl. Med. 2010, 51, 1413-1417
36. Stanek, L. M.; Yang, W.; Angus, S.; Sardi, P. S.; Hayden, M. R.; Hung, G. H.; Bennett, C. F.; Cheng, S. H.; Shihabuddin, L. S. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavrious benefits in the YAC 128 mouse model of Huntington's disease J. Huntington's Dis. 2013, 2, 217-228
37. Hunter, A.; Bordelon, Y.; Cook, I.; Leuchter, A. QEEG measures in Huntington's disease: a pilot study PLoS Curr. 2010, 2, RRN1192
38. Eidelberg, D.; Surmeier, D. J. Brain networks in Huntington disease J. Clin. Invest. 2011, 121, 484-492
39. Gray, M. A.; Egan, G. F.; Ando, A.; Churchyard, A.; Chua, P.; Stout, J. C.; Georgiou-Karistianis, N. Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study Exp. Neurol. 2013, 239, 218-228
40. Wolf, R. C.; Thomann, P. A.; Thomann, A. K.; Vasic, N.; Wolf, N. D.; Landwehrmeyer, G. B.; Orth, M. Brain structure in preclinical Huntington's disease: a multi-method approach Neurodegener. Dis. 2013, 12, 13-22
41. Fecke, W.; Gianfriddo, M.; Gaviraghi, G.; Terstappen, G. C.; Heitz, F. Small molecule drug discovery for Huntington's Disease Drug Discovery Today 2009, 14, 453-464
42. Weiss, A.; Trager, U.; Wild, E. J.; Grueninger, S.; Farmer, R.; Landles, C.; Scahill, R. I.; Lahiri, N.; Haider, S.; Macdonald, D.; Frost, C.; Bates, G. P.; Bilbe, G.; Kuhn, R.; Andre, R.; Tabrizi, S. J. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression J. Clin. Invest. 2012, 122, 3731-3736
43. Baldo, B.; Paganetti, P.; Grueninger, S.; Marcellin, D.; Kaltenbach, L. S.; Lo, D. C.; Semmelroth, M.; Zivanovic, A.; Abramowski, D.; Smith, D.; Lotz, G. P.; Bates, G. P.; Weiss, A. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington's disease Chem. Biol. 2012, 19, 264-275
44. Miller, J. P.; Hughes, R. E. Protein Interactions and Target Discovery in Huntington's Disease. In Neurobiology of Huntington's Disease: Applications to Drug Discovery; Lo, D. C.; Hughes, R. E., Eds.; CRC Press: Boca Raton, FL, 2011.
45. Shirasaki, D. I.; Greiner, E. R.; Al-Ramahi, I.; Gray, M.; Boontheung, P.; Geschwind, D. H.; Botas, J.; Coppola, G.; Horvath, S.; Loo, J. A.; Yang, X. W. Network organization of the huntingtin proteomic interactome in mammalian brain Neuron 2012, 75, 41-57
46. Ehrnhoefer, D. E.; Sutton, L.; Hayden, M. R. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease Neuroscientist 2011, 17, 475-492
47. Hogel, M.; Laprairie, R. B.; Denovan-Wright, E. M. Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression PLoS One 2012, 7, e41152
48. Trevino, R. S.; Lauckner, J. E.; Sourigues, Y.; Pearce, M. M.; Bousset, L.; Melki, R.; Kopito, R. R. Fibrillar structure and charge determine the interaction of polyglutamine protein aggregates with the cell surface J. Biol. Chem. 2012, 287, 29722-29728
49. Kegel, K. B.; Sapp, E.; Alexander, J.; Valencia, A.; Reeves, P.; Li, X.; Masso, N.; Sobin, L.; Aronin, N.; DiFiglia, M. Polyglutamine expansion in huntingtin alters its interaction with phospholipids J. Neurochem. 2009, 110, 1585-1597
50. Khoshnan, A.; Patterson, P. H. The role of IkappaB kinase complex in the neurobiology of Huntington's disease Neurobiol. Dis. 2011, 43, 305-311
51. Zala, D.; Colin, E.; Rangone, H.; Liot, G.; Humbert, S.; Saudou, F. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons Hum. Mol. Genet. 2008, 17, 3837-3846 (Pubitemid 352762847)
52. Jeong, H.; Then, F.; Melia, T. J., Jr.; Mazzulli, J. R.; Cui, L.; Savas, J. N.; Voisine, C.; Paganetti, P.; Tanese, N.; Hart, A. C.; Yamamoto, A.; Krainc, D. Acetylation targets mutant huntingtin to autophagosomes for degradation Cell 2009, 137, 60-72
53. Tang, B.; Seredenina, T.; Coppola, G.; Kuhn, A.; Geschwind, D. H.; Luthi-Carter, R.; Thomas, E. A. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease Neurobiol. Dis. 2011, 42, 459-467
54. Wang, Z. M.; Lashuel, H. A. Discovery of a novel aggregation domain in the huntingtin protein: implications for the mechanisms of Htt aggregation and toxicity Angew. Chem., Int. Ed. 2013, 52, 562-567
55. Thakur, A. K.; Jayaraman, M.; Mishra, R.; Thakur, M.; Chellgren, V. M.; Byeon, I. J.; Anjum, D. H.; Kodali, R.; Creamer, T. P.; Conway, J. F.; Gronenborn, A. M.; Wetzel, R. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism Nat. Struct. Mol. Biol. 2009, 16, 380-389
56. Tam, S.; Spiess, C.; Auyeung, W.; Joachimiak, L.; Chen, B.; Poirier, M. A.; Frydman, J. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation Nat. Struct. Mol. Biol. 2009, 16, 1279-1285
57. Yu, Z. X.; Li, S. H.; Evans, J.; Pillarisetti, A.; Li, H.; Li, X. J. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease J. Neurosci. 2003, 23, 2193-2202 (Pubitemid 36368907)
58. Atwal, R. S.; Desmond, C. R.; Caron, N.; Maiuri, T.; Xia, J.; Sipione, S.; Truant, R. Kinase inhibitors modulate huntingtin cell localization and toxicity Nat. Chem. Biol. 2011, 7, 453-460
59. Caviston, J. P.; Holzbaur, E. L. Huntingtin as an essential integrator of intracellular vesicular trafficking Trends Cell Biol 2009, 19, 147-155
60. Qin, Z. H.; Wang, Y.; Sapp, E.; Cuiffo, B.; Wanker, E.; Hayden, M. R.; Kegel, K. B.; Aronin, N.; DiFiglia, M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction J. Neurosci. 2004, 24, 269-281 (Pubitemid 38181691)
61. Mielcarek, M.; Benn, C. L.; Franklin, S. A.; Smith, D. L.; Woodman, B.; Marks, P. A.; Bates, G. P. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease PLoS One 2011, 6, e27746
62. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, J. V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 2009, 325, 834-840
63. Mielcarek, M.; Landles, C.; Weiss, A.; Bradaia, A.; Seredenina, T.; Inuabasi, L.; Osborne, G. F.; Wadel, K.; Touller, C.; Butler, R.; Robertson, J.; Franklin, S. A.; Smith, D. L.; Park, L.; Marks, P. A.; Wanker, E. E.; Olson, E. N.; Luthi-Carter, R.; van der Putten, H.; Beaumont, V.; Bates, G. P. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration PLoS Biol. 2013, 11, e1001717
64. Moumne, L.; Campbell, K.; Howland, D.; Ouyang, Y.; Bates, G. P. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease PLoS One 2012, 7, e31080
65. Bobrowska, A.; Paganetti, P.; Matthias, P.; Bates, G. P. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease PLoS One 2011, 6, e20696
66. Benn, C. L.; Butler, R.; Mariner, L.; Nixon, J.; Moffitt, H.; Mielcarek, M.; Woodman, B.; Bates, G. P. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease PLoS One 2009, 4, e5747
67. Burli, R. W.; Dominguez, C. Selective HDAC Class IIa Inhibitors as Potential Therapeutics for Huntington's Disease. Presented at the 242nd National Meeting of the American Chemical Society, Denver, CO, August 28-September 1, 2011.
68. Burli, R. W.; Luckhurst, C. A.; Aziz, O.; Matthews, K. L.; Yates, D.; Lyons, K. A.; Beconi, M.; McAllister, G.; Breccia, P.; Stott, A. J.; Penrose, S. D.; Wall, M.; Lamers, M.; Leonard, P.; Muller, I.; Richardson, C. M.; Jarvis, R.; Stones, L.; Hughes, S.; Wishart, G.; Haughan, A. F.; O'Connell, C.; Mead, T.; McNeil, H.; Vann, J.; Mangette, J.; Maillard, M.; Beaumont, V.; Munoz-Sanjuan, I.; Dominguez, C. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease J. Med. Chem. 2013, 56, 9934-9954
69. Vecsei, L.; Szalardy, L.; Fulop, F.; Toldi, J. Kynurenines in the CNS: recent advances and new questions Nat. Rev. Drug Discovery 2013, 12, 64-82
70. Schwarcz, R.; Bruno, J. P.; Muchowski, P. J.; Wu, H. Q. Kynurenines in the mammalian brain: when physiology meets pathology Nat. Rev. Neurosci. 2012, 13, 465-477
71. Toledo-Sherman, L. Optimization of Kynurenine Monooxygenase (KMO) Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington's Disease. Presented at the 2013 Zing Medicinal Chemistry Conference, Napa Valley, CA, U.S., 2013.
72. Tabrizi, S. J.; Reilmann, R.; Roos, R. A.; Durr, A.; Leavitt, B.; Owen, G.; Jones, R.; Johnson, H.; Craufurd, D.; Hicks, S. L.; Kennard, C.; Landwehrmeyer, B.; Stout, J. C.; Borowsky, B.; Scahill, R. I.; Frost, C.; Langbehn, D. R. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data Lancet Neurol. 2012, 11, 42-53
73. Tabrizi, S. J.; Scahill, R. I.; Owen, G.; Durr, A.; Leavitt, B. R.; Roos, R. A.; Borowsky, B.; Landwehrmeyer, B.; Frost, C.; Johnson, H.; Craufurd, D.; Reilmann, R.; Stout, J. C.; Langbehn, D. R. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data Lancet Neurol. 2013, 12, 637-649
74. Tang, C. C.; Feigin, A.; Ma, Y.; Habeck, C.; Paulsen, J. S.; Leenders, K. L.; Teune, L. K.; van Oostrom, J. C.; Guttman, M.; Dhawan, V.; Eidelberg, D. Metabolic network as a progression biomarker of premanifest Huntington's disease J. Clin. Invest. 2013, 123, 4076-4088